Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
NCT02158091Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of duvelisib in chronic lymphocytic leukemia (CLL), sponsored by Dana-Farber Cancer Institute. Started Jun 2014; status: active, not recruiting.
02
Drugs
duvelisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02158091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02158091.